Atox Bio Ltd   Report issue

For profit Phase 3
Founded: Ness Ziona Israel (2003)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2010
NCT01166984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Atox Bio Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

reltecimod (4 trials)

sodium chloride (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Communicable Diseases (Phase 3)

Fasciitis (Phase 3)

Fasciitis, Necrotizing (Phase 3)

Fournier Gangrene (Phase 3)

Gangrene (Phase 3)

Infections (Phase 3)

Peritonitis (Phase 2)

Sepsis (Phase 2)

Soft Tissue Infections (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2